The Microtubule Associated Protein Tau pipeline drugs market research report outlays comprehensive information on the Microtubule Associated Protein Tau targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Microtubule Associated Protein Tau pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Metabolic Disorders, Cardiovascular, and Infectious Disease which include the indications Alzheimer’s Disease, Tauopathies, Type 2 Diabetes, Amyloidosis, Stroke, Acute Ischemic Stroke, and Human Immunodeficiency Virus (HIV) Infections (AIDS). It also reviews key players involved in Microtubule Associated Protein Tau targeted therapeutics development with respective active and dormant or discontinued products.
The Microtubule Associated Protein Tau pipeline targets constitutes close to 110 molecules. Out of which, approximately 92 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 2, 9, 12, 1, 42, and 25 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 12, and 6 molecule.
Microtubule Associated Protein Tau overview
Microtubule-associated protein tau (tau) is a protein that is found in the microtubules of neurons. Tau helps to stabilize microtubules and keep them from falling apart. Microtubules are important for many cellular functions, including cell division, transport of materials within cells, and the maintenance of cell shape.
For a complete picture of Microtubule Associated Protein Tau’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
